WallStSmart

Healthcare Triangle Inc (HCTI)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 282771% more annual revenue ($56.69B vs $20.04M). NVS leads profitability with a 22.5% profit margin vs -69.7%. NVS earns a higher WallStSmart Score of 51/100 (C-).

HCTI

Hold

41

out of 100

Grade: D

Growth: 5.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -2.84

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HCTI.

NVSSignificantly Overvalued (-63.9%)

Margin of Safety

-63.9%

Fair Value

$92.92

Current Price

$150.88

$57.96 premium

UndervaluedFair: $92.92Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCTI3 strengths · Avg: 9.7/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
166.1%10/10

Revenue surging 166.1% year-over-year

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$291.32B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

HCTI4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.53M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-26.5%2/10

ROE of -26.5% — below average capital efficiency

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.562/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : HCTI

The strongest argument for HCTI centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 166.1% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bear Case : HCTI

The primary concerns for HCTI are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

HCTI profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.

HCTI carries more volatility with a beta of 1.12 — expect wider price swings.

HCTI is growing revenue faster at 166.1% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 41/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Healthcare Triangle Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Healthcare Triangle, Inc. is a healthcare information technology company. The company is headquartered in Pleasanton, California.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?